Why you should join Kayentis
29 April 2024
At Kayentis, we value each individual and we form a community that goes beyond the
RESOURCES
Go Back
Read More »
Read More »
Read More »
Read More »
Read More »
Read More »
Emerging Biopharma & Biotech (EBP) – 5 key success factors for your clinical trials
With so much at stake, consider partnering with an eCOA and DCT expert!
Kayentis offers a unified platform featuring trustworthy services to ensure the success of electronic Clinical Outcome Assessment (eCOA) and decentralized clinical trials (DCT):
- 18+ years’ eCOA experience navigating diverse clinical trial challenges
- A unified platform for decentralized clinical trials enhancing patient and site experience
- Trusted partnership ensuring top-quality service delivery
- Clinical and scientific experts empowering and supporting your teams
- Therapeutic expertise addressing the unique needs of specific populations
Key Words:
- eCOA
- DCT
- Biopharma
- Biotech
- ePRO
- clinical trial
Learn more:
Rethinking pediatric clinical trials: guidelines from pediatric experts
2 April 2024
In this last episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement
Overcoming challenges in long-lasting pediatric clinical trials – Insights from site experts
26 March 2024
In this third episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement
Tackling the specificities of NASH/MASH clinical trials
26 March 2024
Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating
Mastering pediatric asthma clinical trials
19 March 2024
Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of
The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs
14 March 2024
NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally
Last update : 26 July 2023